Domov › Ťažká depresívna porucha › Ohio
Klinické štúdie Ťažká depresívna porucha v štáte Ohio
29 štúdií pre Ťažká depresívna porucha hľadá účastníkov v zariadeniach v štáte Ohio.
Mestá v štáte Ohio
Oficiálny text štúdie (anglicky)
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Patient Priority Clinical Sites LLC, Cincinnati
Prebieha náborFáza 3
Vek 18 až 74 · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT07573176Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Patient Priority Clinical Sites LLC, Cincinnati
- The Ohio State University, Columbus
Prebieha náborFáza 3
Vek 18 až 74 · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06559306Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Quest Therapeutics of Avon Lake, Avon Lake
- University of Cincinnati Medical Center, Cincinnati
- The Ohio State University, Columbus
Prebieha náborFáza 3
Vek 18 až 65 · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT05850689A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- University of Cincinnati, Cincinnati
Prebieha náborFáza 3
Vek 12 až 17 · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07227454Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Cincinnati
Prebieha náborFáza 3
Vek 18 až 65 · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06830044A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Independence
Prebieha náborFáza 4
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 9. 2026 · NCT07105111A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Independence
- Seaport Investigator Site, North Canton
Prebieha náborFáza 2
Vek 18 až 65 · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT07065240ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- Neuro-Behavioral Clinical Research, North Canton
Prebieha náborFáza 2
Vek 18 až 65 · Všetky pohlavia · Aktualizované 14. 9. 2026 · NCT07284667A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Insight Clinical Trials, Independence
Prebieha náborFáza 3
Vek 18 až 74 · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT07076407A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Columbus
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 2. 9. 2026 · NCT07610473Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- The Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
Prebieha nábor
Vek 22 až 70 · Všetky pohlavia · Aktualizované 28. 8. 2026 · NCT06423430Positive Processes and Transition to Health (PATH)
- Case Western Reserve University, Cleveland
Prebieha nábor
Vek 18 až 65 · Všetky pohlavia · Aktualizované 19. 8. 2026 · NCT06093906NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Mason
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 11. 8. 2026 · NCT06911112A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Cleveland Clinic, Cleveland
Prebieha náborFáza 3
Vek 18 až 74 · Všetky pohlavia · Aktualizované 10. 8. 2026 · NCT07592689Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains
- Lindner Center of Hope, Mason
Prebieha náborFáza 1/2
Vek 18 až 60 · Všetky pohlavia · Aktualizované 3. 8. 2026 · NCT06795451A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Neuro-Behavioral Clinical Research, North Canton
Prebieha náborFáza 3
Vek 18 až 74 · Všetky pohlavia · Aktualizované 3. 8. 2026 · NCT06775379Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Insight Clinical Trials LLC, Independence
Prebieha náborFáza 2
Vek 18 až 64 · Všetky pohlavia · Aktualizované 3. 8. 2026 · NCT06547489A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Insight Clinical Trials LLC, Independence
Prebieha náborFáza 2
Vek 18 až 64 · Všetky pohlavia · Aktualizované 27. 7. 2026 · NCT07115329Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Avon Lake
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 7. 2026 · NCT06966401Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Clinical Research Site, Cincinnati
- Clinical Research Site, Cincinnati
Prebieha náborFáza 3
Vek 18 až 65 · Všetky pohlavia · Aktualizované 24. 7. 2026 · NCT07484217A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
- The Ohio State University Department of Psychiatry, Columbus
Prebieha náborFáza 2
Vek 21 až 65 · Všetky pohlavia · Aktualizované 23. 7. 2026 · NCT06820723A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Quest Therapeutics of Avon /ID# 277550, Avon Lake
- OSU Psychiatry Department /ID# 277529, Columbus
Prebieha náborFáza 2
Vek 18 až 65 · Všetky pohlavia · Aktualizované 15. 6. 2026 · NCT07276997A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- The Ohio State University, Columbus
- Neuro Behavioral Clinical Research, Inc., North Canton
Prebieha náborFáza 2
Vek 18 až 65 · Všetky pohlavia · Aktualizované 11. 5. 2026 · NCT06524830Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation
- Cincinnati Childrens Hospital Medical Center, Cincinnati
Prebieha nábor
Vek 14 až 18 · Všetky pohlavia · Aktualizované 11. 2. 2026 · NCT07217444Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #109, Beachwood
Prebieha náborFáza 2
Vek 18 až 65 · Všetky pohlavia · Aktualizované 20. 1. 2026 · NCT06633016Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Avon Lake
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 10. 2025 · NCT06786624Mechanisms of Rumination Change in Adolescent Depression
- Nationwide Children's Hospital, Columbus
- The Ohio State University, Columbus
Prebieha nábor
Vek 14 až 17 · Všetky pohlavia · Aktualizované 11. 8. 2025 · NCT03859297Study of ALTO-300 in MDD
- Site 202, Cincinnati
Prebieha náborFáza 2
Vek 18 až 70 · Všetky pohlavia · Aktualizované 24. 7. 2025 · NCT05922878A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Clinical Research Site, Cincinnati
Prebieha náborFáza 4
Vek 18 až 65 · Všetky pohlavia · Aktualizované 23. 1. 2025 · NCT06223880Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.